Notice of annual general meeting in Biovitrum AB (publ), April 24, 2008



The shareholders in  Biovitrum AB (publ),  Reg. No. 556038-9321,  are
hereby summoned to the annual general meeting (the "Meeting"), to  be
held on  Thursday 24  April  2008 at  4.00  p.m. at  Berns  Salonger,
Berzelii Park, Stockholm, Sweden.

Participation, etc
Shareholders who wish to attend the  Meeting must be recorded in  the
share register maintained by VPC  AB (the Swedish Central  Securities
Depository) on Friday 18 April 2008,  and must notify the company  of
their intention to  participate in  the Meeting not  later than  4.00
p.m.  on   Friday   18   April   2008   at   Biovitrum's   web   site
www.biovitrum.com, by mail  to Biovitrum AB  (publ), "Annual  General
Meeting", 112 76 Stockholm, Sweden or by  phone no. +46 8 697 34  27.
The notification shall set forth the name, address, telephone  number
(daytime), personal/corporate identity number,  the number of  shares
held and,  when  applicable, information  about  representatives  and
assistants. Per the day  of this notice  there are 45,622,700  shares
and votes outstanding in the company.

Nominee shares
Shareholders, whose  shares have  been registered  in the  name of  a
nominee  through  the   trust  department  of   a  bank  or   similar
institution, must temporarily re-register  their shares in their  own
names in  the  shareholders' register  maintained  by VPC  AB  to  be
entitled to  participate in  the  Meeting. Shareholders  must  inform
their nominee of  such re-registration  well before  Friday 18  April
2008, when such re-registration must have been executed.

Proxy, etc
Shareholders represented by proxy shall issue a written and dated
power of attorney for the proxy. If the power of attorney is issued
on behalf of a legal entity, a certified copy of a registration
certificate for the legal entity shall be appended. The power of
attorney and the registration certificate may not be older than one
year. The power of attorney in original and, when applicable, the
registration certificate, should be submitted to the company by mail
at the address indicated above well before the Meeting. A proxy form
is held available at the company's web site, www.biovitrum.com, and
will also be sent to shareholders who so request and who inform the
company of their postal address.


Attachment: Notice of annual general meeting in Biovitrum AB (publ)
2008.


For more information, please contact:

Biovitrum AB (publ)
Martin Nicklasson,
CEO
Phone: +46 8 697 20 00
martin.nicklasson@biovitrum.com

About Biovitrum
Biovitrum is a pharmaceutical company with operations in Sweden and
in the UK. Biovitrum has currently a research portfolio with several
projects in clinical and preclinical phases for a number of well
defined specialist indications as well as for common diseases within
obesity, diabetes, inflammation and eye diseases. Biovitrum develops
and produces protein-based drugs on a contractual basis and markets a
range of specialist pharmaceuticals primarily in the Nordic
countries. Biovitrum has revenues of approximately SEK 1.2 billion
and around 500 employees. Biovitrum's share is listed on the OMX
Nordic Exchange in Stockholm since September 15, 2006. For more
information see www.biovitrum.com.

Attachments

Complete Notice